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SUMMARY
Reactive astrocytes influence post-injury recovery, repair, and pathogenesis of the mammalian 
CNS. Much of the regulation of astrocyte reactivity, however, remains to be understood. Using 
genetic loss and gain-of-function analyses in vivo, we show that the conserved MAP3K13 (also 
known as leucine zipper-bearing kinase [LZK]) promotes astrocyte reactivity and glial scar 
formation after CNS injury. Inducible LZK gene deletion in astrocytes of adult mice reduced 
astrogliosis and impaired glial scar formation, resulting in increased lesion size after spinal cord 
injury. Conversely, LZK overexpression in astrocytes enhanced astrogliosis and reduced lesion 
size. Remarkably, in the absence of injury, LZK overexpression alone induced widespread 
astrogliosis in the CNS and upregulated astrogliosis activators pSTAT3 and SOX9. The 
identification of LZK as a critical cell-intrinsic regulator of astrocyte reactivity expands our 
understanding of the multicellular response to CNS injury and disease, with broad translational 
implications for neural repair.
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In Brief
Reactive astrocytes are recognized increasingly for their role in CNS injury and disease. Chen et 
al. find that leucine zipper-bearing kinase (LZK) is a positive regulator of astrocyte reactivity that 
controls glial scar formation after spinal cord injury. These findings have broad implications for 
understanding injury responses and promoting neural repair.
INTRODUCTION
Astrocytes have diverse functions in the healthy CNS and participate in CNS 
pathophysiology. In the healthy CNS, astrocytes provide structural and metabolic support, 
regulate neurotransmitter uptake and synaptic transmission, and help maintain the blood-
brain barrier (Ben Haim and Rowitch, 2017; Khakh and Sofroniew, 2015). Under 
pathological conditions, astrocytes become reactive, undergoing a spectrum of phenotypic 
changes from upregulation of molecular markers and cytoskeletal hypertrophy to cell 
proliferation (Gallo and Deneen, 2014; Liddelow and Barres, 2017). Reactive astrogliosis 
(or simply astrogliosis), a collective term for astrocytic responses to insults, is a common 
feature across a wide range of neurological conditions, including traumatic injury, stroke, 
epilepsy, and neurodegenerative diseases (Liddelow et al., 2017; Pekny et al., 2016). 
Understanding the role of astrogliosis and its molecular regulation will aid in the design of 
therapeutic intervention to promote recovery and repair following CNS injury and disease.
Following traumatic injury to the CNS such as a spinal cord injury, astrocytes display a 
gradient of responses centered around the lesion site (Burda and Sofroniew, 2014). Reactive 
astrocytes form a dense scar just outside the fibrotic lesion core, which consists of mainly 
non-neural cells such as fibroblast-like cells and macrophages. The role of reactive 
astrocytes and the glial scar in recovery and repair after CNS injury is complex. It is 
generally thought that the glial scar presents a physical barrier and produces chondroitin 
sulfate proteoglycans (CSPGs) that inhibit axon growth and regeneration (Bradbury et al., 
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2002; Silver and Miller, 2004). However, akin to wound repair following skin lesions, 
reactive astrocytes and the glial scar also have beneficial roles in confining the injury site, 
repairing the blood-brain barrier, and limiting the spread of inflammation (Bush et al., 1999; 
Faulkner et al., 2004; Herrmann et al., 2008; Sabelström et al., 2013; Wanner et al., 2013). 
Recent evidence indicates that, contrary to common belief, the astrocyte scar may even aid 
in axon regeneration (Anderson et al., 2016).
Despite the increasingly recognized importance of reactive astrogliosis in the pathogenesis 
and outcome of neurological conditions, our understanding of its molecular regulation 
remains limited, especially regarding cell-intrinsic mechanisms. We have previously 
identified leucine zipper-bearing kinase (LZK) (MAP3K13), a conserved mitogen-activated 
protein kinase kinase kinase (MAPKKK) upstream of c-Jun N-terminal kinase (JNK) in the 
MAPK pathway, as a neuron-intrinsic promoter of axonal growth in cultured CNS neurons 
(Chen et al., 2016). Here, we investigated the in vivo role of LZK after CNS injury. We 
found that spinal cord injury induces LZK expression prominently in astrocytes. Genetic 
gain and loss-of-function analyses in mice indicated that LZK is an important positive 
regulator of astrocyte reactivity and postinjury glial scar formation. Our study opens new 
avenues to manipulate astrogliosis and to understand its complex roles in the pathogenesis of 
and recovery from CNS injury and disease.
RESULTS
Spinal Cord Injury Upregulates LZK Expression in Astrocytes
LZK is normally expressed in the CNS of embryonic and adult mice based on mouse 
transcriptomic data (Shen et al., 2012). As the first step in characterizing the in vivo role of 
LZK in mammalian CNS injury response, the expression pattern of endogenous LZK was 
examined using immunostaining following dorsal spinal cord crush injury (see Experimental 
Procedures). In the uninjured spinal cord, low baseline expression of the astrocyte marker 
glial fibrillary astrocyte protein (GFAP) and LZK were detectable by immunofluorescence 
(Figure 1A). Two weeks after injury, GFAP was upregulated in astrocytes as expected 
(Burda and Sofroniew, 2014; Sofroniew, 2014) (Figure 1A). Concurrently, LZK 
immunoreactivity was markedly increased in the perilesional region and co-labeled with 
GFAP, especially in the gray matter (Figures 1A and S1A). These observations indicate that 
injury increases LZK expression in astrocytes and raise the possibility that LZK may be 
functionally involved in the astrocytic response to CNS injury.
Inducible LZK Deletion in Adult Astrocytes Impairs Astrogliosis and Glial Scar Formation 
after Spinal Cord Injury
To test the role of astrocytic LZK in astrogliosis after CNS injury, we generated tamoxifen-
inducible, astrocyte-specific LZK knockout mice (GFAP-CreERT2;LZKf/f [LZK conditional 
knockout]) along with LZKf/f littermate controls (Figures 1B and 1C). We administered 
tamoxifen to adult mice at ages 8–10 weeks during a 5-day period and waited for another 
week before inducing spinal cord injury (see Experimental Procedures). Following 
tamoxifen treatment, GFAP expression in the spinal cords of uninjured mice was 
comparable between control (LZKf/f) and astrocytic LZK knockout (GFAP-
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CreERT2;LZKf/f) mice (Figure S1). After spinal cord injury, astrocytic LZK expression was 
induced in the spinal cords of LZKf/f control mice but not in GFAP-CreERT2;LZKf/f mice, 
verifying efficient deletion of LZK in astrocytes (Figures 1D and S1B).
Focal trauma to the spinal cord in mice results in a GFAP-sparse fibrotic lesion core 
surrounded by a GFAP-dense astroglial scar, which represents an extreme form of 
astrogliosis that gradually tapers off at increasing distances from the lesion core (Burda and 
Sofroniew, 2014). At 2 weeks after spinal cord injury, at which time the glial scar is 
considered mature based on previous studies in mice (Herrmann et al., 2008; Herrmann et 
al., 2010; Wanner et al., 2013), we analyzed the status of astrogliosis by its prominent 
features as follows: maturation of the scar border as assessed by orientation of astrocytic 
processes together with lesion size, upregulation of cytoskeletal proteins GFAP and 
vimentin, and astrocyte proliferation (Sofroniew, 2014). In tamoxifen-treated LZKf/f control 
mice, cellular processes of astrocytes were predominantly oriented parallel to the fibrotic-
astroglial border (Figure 2A). In mice depleted of astrocytic LZK, astrocytes at the lesion 
border formed a less compact scar border with astrocytic processes often perpendicular to 
the lesion border (Figure 2A), which is characteristic of impaired astrocyte-fibroblast 
segregation and scar formation. Correspondingly, lesion size was increased by ~50% in mice 
lacking astrocytic LZK (Figure 2B). In control mice, spinal cord injury resulted in an 
increase of ~2- to 3-fold in GFAP immunoreactivity immediately adjacent to the lesion core, 
and GFAP upregulation was diminished toward baseline at ~1.5 mm away from the injury 
site (Figure 2C). In comparison, within the same region, such injury-dependent GFAP 
upregulation was diminished by ~20% in mice lacking astrocytic LZK (Figure 2C). 
Likewise, injury-induced upregulation of vimentin, known to occur in reactive astrocytes 
(Zamanian et al., 2012), was reduced by ~20% immediately surrounding the lesion core in 
mice lacking astrocytic LZK (Figures 3A and 3C).
CNS injury induces astroglial proliferation within 2 weeks following trauma, with the 
highest number of proliferating astrocytes present closest to the lesion site following spinal 
cord injury (Burda and Sofroniew, 2014; Sofroniew, 2014; Wanner et al., 2013). We 
identified proliferating astrocytes based on immunofluorescence co-labeling of the cell 
proliferation marker Ki67 and the astroglial nuclear marker SOX9 (Sun et al., 2017) (Figure 
3B). Seven days after spinal cord injury, the number of Ki67+SOX9+ cells immediately 
surrounding the lesion site was decreased by ~40% in mice lacking LZK in adult astrocytes 
as compared to control mice (Figures 3B and 3D). We also examined astroglial proliferation 
following bromodeoxyuridine (BrdU) incorporation into GFAP+ cells (Wanner et al., 2013) 
and observed a 25% reduction in BrdU+GFAP+ cell number surrounding the injury site in 
mice lacking astrocytic LZK (Figure S2). Taken together, these observations indicate that 
following spinal cord injury, loss of LZK in astrocytes impaired astrogliosis as assessed by 
its hallmarks of GFAP/vimentin upregulation, astroglial scar formation, and astrocyte 
proliferation, thereby supporting LZK as an important regulator of reactive astrogliosis.
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Inducible LZK Overexpression in Adult Astrocytes Enhances Reactive Astrogliosis after 
Spinal Cord Injury
To complement the LZK loss-of-function analyses above, we next conducted analyses of 
genetic gain of function for LZK after CNS injury. To do this, we generated mice that 
overexpress LZK in astrocytes upon tamoxifen treatment (GFAP-CreERT2;LZKOE) (Figures 
4A and 4B). In this transgenic line, the LZK coding sequence is linked to that of the red 
fluorescent protein tdTomato (tdT) through the T2A peptide, thereby enabling fluorescent 
identification of LZK-overexpressing astrocytes. We treated 8- to 10-week-old mice with 
tamoxifen and then induced spinal cord injury (see Experimental Procedures). We were 
intrigued that mice with astrocyte-specific LZK overexpression had poor survival, with only 
12% survival after 2 weeks post-injury (n = 26), compared to a 95% survival rate for control 
mice (n = 35) that underwent the same procedures. Astrocytic LZK-overexpressing mice lost 
weight after tamoxifen treatment, even before spinal cord injury. The cause of death remains 
to be determined.
In the injured spinal cords of astrocytic LZK-overexpressing mice, a subset of GFAP+ 
astrocytes were tdT+ with intensely upregulated LZK (Figure 4C), demonstrating induction 
of the LZK-tdT transgene. As expected, control mice (tamoxifen-treated LZKOE mice 
without GFAP-CreERT2) did not exhibit any tdT expression (Figure 4C). Consistent with 
previous observations (Herrmann et al., 2008; Wanner et al., 2013), astrocytes formed a 
compact scar 2 weeks after spinal cord injury in control mice (Figure 4D). Astrocytic LZK-
overexpressing mice also exhibited a compact scar (Figure 4D). However, the average lesion 
size in mice with astrocytic LZK overexpression was reduced to ~60% of that of the control 
mice, indicating that astrocytic LZK overexpression led to a more compact injury site 
(Figure 4E). It is striking that at the site of injury, LZK-overexpressing astrocytes lined the 
lesion border, as depicted by the presence of GFAP and tdT double-positive (GFAP+tdT+) 
astrocytes and their processes enveloping the lesion core (Figure 4D, bottom panels). 
Immediately surrounding the lesion core, both LZK-overexpressing and control mice 
showed similar levels of GFAP expression levels (Figure 4F, zone 1). However, at 1.5 mm 
from the injury site, where GFAP signal intensity typically tapered toward baseline in the 
control group (38% of peak GFAP expression as measured at the scar border), GFAP 
intensity was sustained at ~70% of peak levels in mice overexpressing LZK (Figure 4F, zone 
6). Even beyond 2 mm from the lesion, astrocytic LZK-overexpressing mice exhibited an 
almost 2-fold increase in GFAP levels compared to the control mice (Figure 4F, zone 9). 
Consistent with this, in LZK-overexpressing mice, astrocytes near the injury site displayed 
morphologies of augmented hypertrophy, compared to control mice after spinal cord injury 
(Figure 4C). A different surgeon was able to reproduce this key finding of enhanced 
astrogliosis, leading to a more compact injury site in astrocytic LZK-overexpressing mice 
(Figures S3A–S3C). LZK-tdT-overexpressing astrocytes densely decorated the injury site 
and exhibited elongated processes (Figure S3B), as previously ascribed to reactive astrocytes 
forming the glial scar border (Wanner et al., 2013).
In summary, mice overexpressing astrocytic LZK reproducibly exhibited enhanced 
astrogliosis and a more compact injury site after spinal cord injury. Corroborating our results 
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with the astrocyte-specific LZK knockout mice described above, these data indicate that 
LZK promotes astrogliosis and glial scar formation after CNS injury.
LZK Overexpression in Adult Astrocytes Alone Induces Widespread Astrogliosis in the 
Absence of CNS Injury
Given that overexpressing LZK in astrocytes enhanced astrogliosis after spinal cord injury, 
we next asked whether such an effect is dependent on injury. Three weeks after the end of 
tamoxifen treatment in adult mice, we examined GFAP expression in the CNS of controls 
(LZKOE) and mice overexpressing astrocytic LZK (GFAP-CreERT2;LZKOE). In the spinal 
cords of uninjured controls, baseline GFAP expression was detectable in the spinal cords and 
especially in the white matter by immunofluorescence (Figures 5A and 5B). Following 
induction of astrocyte-specific LZK overexpression, we observed a marked increase in 
GFAP immunoreactivity throughout the spinal cord, with the most pronounced upregulation 
detected in the gray matter, where only a low level of baseline GFAP immunoreactivity was 
present in the control group (Figures 5A and 5B). Quantitative analyses revealed that 
astrocyte-specific LZK overexpression led to an ~2-fold increase in GFAP immunoreactivity 
in the spinal cords of uninjured mice (Figure 5C). At higher magnifications, co-localization 
of induced LZK and tdT along with upregulated GFAP could be discerned clearly in the 
spinal cords of uninjured GFAP-CreERT2;LZKOE mice (Figure 5D).
Such upregulation of GFAP immunoreactivity in uninjured mice overexpressing astrocytic 
LZK was not restricted to the spinal cord. In control mice, baseline levels of GFAP 
immunoreactivity were observed throughout the brain, with moderately higher expression in 
several regions, including the hippocampus and some white matter tracts (e.g., corpus 
callosum) (Figure 5E). In contrast, astrocytic LZK overexpression led to a dramatic increase 
in GFAP immunoreactivity in the cerebral cortex, hypothalamus, and many other regions 
throughout the brain (Figure 5E). As in the spinal cord, increased GFAP upregulation was 
most pronounced in the gray matter, likely because of the higher expression of the LZK-tdT 
transgene there. Quantitative analyses revealed that astrocytic LZK overexpression led to an 
~10-fold increase in GFAP immunoreactivity in the cerebral cortex, where baseline levels of 
GFAP in control mice were low (Figure 5F). It is interesting to note that only a small subset 
(~13%) of these GFAP+ astrocytes co-labeled with tdT, suggesting that LZK overexpression 
may lead to both cell-autonomous and non-cell-autonomous induction of astrocyte reactivity.
To confirm that astrocytic LZK overexpression affects general astrogliosis and not merely 
the expression of GFAP, we also examined vimentin expression and astroglial proliferation. 
In the absence of any injury, astrocytic LZK overexpression markedly increased vimentin 
expression and astrocyte proliferation broadly in the CNS, with the latter assessed by Ki67 
and GFAP co-labeling (Figure 6). Therefore, astrocytic overexpression of LZK alone was 
sufficient to upregulate molecular markers of astrogliosis and to promote astroglial 
proliferation in the absence of any injury.
LZK Is an Upstream Activator of SOX9 and STAT3 with Mitogenic Effects
To begin identifying downstream effectors through which LZK promotes astrogliosis, we 
assessed the activation and expression of two key transcription factors that were previously 
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shown to regulate the astrocytic response to spinal cord injury, SOX9 and signal transducer 
and activator of transcription 3 (STAT3). Genetic loss-of-function studies previously 
implicated SOX9 in promoting astrocyte reactivity and the upregulation of associated 
CSPGs (McKillop et al., 2013). SOX9 expression levels in astrocytes also are elevated after 
CNS insults as assessed with stroke and amyotrophic lateral sclerosis (ALS) models (Sun et 
al., 2017). Outside the periventricular region, the central canal, and neurogenic areas, SOX9 
predominantly labels the nuclei of astrocytes (Sun et al., 2017). We performed SOX9 
immunostaining and detected an ~10% increase in the number of SOX9+ cells in the 
cerebral cortices and spinal cords of uninjured mice overexpressing astrocytic LZK (Figures 
7A–7D). This was accompanied by an ~2-fold increase in SOX9 immunofluorescence 
intensity per cell (Figures 7A–7D). Such an increase in SOX9+ cell number was likely the 
result of increased astrocyte cell proliferation (Figures 6C and 6D). Thus, in the absence of 
any injury, overexpressing LZK in astrocytes alone was sufficient to elevate both SOX9 
levels in astrocytes and the number of SOX9+ cells.
STAT3, another astrogliosis-associated transcription factor that acts in the Janus kinase 
(JAK)-STAT signaling pathway, has been shown to mediate injury-dependent astrogliosis 
and glial scar formation (Herrmann et al., 2008; Okada et al., 2006). Activation of STAT3 
can be detected by phosphorylation at tyrosine 705 (Herrmann et al., 2008), hereafter 
referred to as pSTAT3. We found few pSTAT3+ cells or pSTAT3+GFAP+ astrocytes in the 
spinal cords of uninjured control mice (Figures 7E, S3D, and S3E). In contrast, uninjured 
mice with astrocyte-specific LZK overexpression had an ~10-fold increase in the number of 
pSTAT3+ cells and pSTAT3+ astrocytes (Figures 7E, S3D, and S3E), some of which co-
labeled with tdT (Figure 7E). After spinal cord injury, increased numbers of pSTAT3+ cells 
and pSTAT3+ astrocytes also were observed at the injury site and perilesional region in mice 
overexpressing astrocytic LZK, as compared with injured control mice (Figures S3A, S3B, 
S3D, and S3E).
Previously, we identified JNK as the main downstream effector of the LZK signal pathway 
promoting axon outgrowth in cultured CNS neurons (Chen et al., 2016). Curiously, here, 
JNK activation was rarely detected in LZK-overexpressing astrocytes in the absence of 
injury in vivo (Figure S4). Notably, overexpressing LZK in parvalbumin (Pv)-positive 
neurons using the same inducible transgenic overexpression line (Pv-Cre;LZKOE) did not 
cause animal death or alteration in the gross morphology of Pv-expressing neurons in the 
cerebellum (Figure S5), arguing against non-specific, toxic effects of LZK overexpression.
In summary, these data suggest that LZK promotes astrogliosis by upregulating SOX9 and 
activating STAT3, two known regulators of astrocyte reactivity. Furthermore, JNK does not 
appear to be a robust target of LZK in adult astrocytes, suggesting cell-type-specific and 
context-dependent LZK signaling.
DISCUSSION
Reactive astrocytes are recognized increasingly for their important contributions to injury 
response, disease pathogenesis, plasticity, and repair in the CNS (Pekny et al., 2016). A 
better understanding of the molecular underpinning of reactive astrogliosis provides valuable 
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tools to manipulate this process, unravel its complex functions, and affect the outcome of a 
multitude of neurological conditions. Our study revealed LZK to be a positive, cell-intrinsic 
regulator of astrogliosis, as evidenced by its ability to promote the expression of reactive 
astrocyte markers, astrocyte cell proliferation, and maturation of the glial scar. Notably, 
overexpressing LZK in astrocytes alone was sufficient to drive widespread astrogliosis 
throughout the otherwise unperturbed CNS. These data support LZK as a potential target of 
astroglial manipulation for improving the outcome in a spectrum of CNS injuries and 
diseases.
Genetic loss and gain of LZK function in astrocytes decreased and increased astrogliosis, 
respectively, as assessed by multiple established features defining astrogliosis, 
demonstrating LZK as a cell-intrinsic regulator of astrocyte reactivity. However, the effect of 
LZK overexpression appeared to “spill over” to other astrocytes: although only a relatively 
small subset of astrocytes (~13%) in GFAP-CreERT2;LZKOE mice overexpressed LZK, as 
assessed by expression of its reporter tdT, GFAP was systemically upregulated throughout 
the CNS, even in the absence of an injury or other insult. Thus, LZK may promote 
astrogliosis both cell autonomously and non-cell autonomously. It remains to be excluded, 
however, that LZK-overexpressing astrocytes may simply give rise to progeny that do not 
express the LZK-tdT transgene. Following spinal cord injury, LZK-overexpressing 
astrocytes were found to line the lesion border with an elongated morphology, which is 
consistent with the possibility that LZK regulates the astrocyte response to a gradient of 
instructional cues emanating from the lesion core (Burda and Sofroniew, 2014). The effects 
of astrocytic LZK overexpression on other injury responses such as blood-brain barrier 
permeability and the spread of inflammation remain to be investigated.
STAT3, SOCS3 (repressor of STAT3), and nuclear factor κB (NF-κB) are among the key 
molecules previously shown to regulate astrogliosis and lesion size after spinal cord injury 
(Brambilla et al., 2005; Herrmann et al., 2008; Okada et al., 2006). SOCS3 deletion 
enhances glial scar formation and wound healing after spinal cord injury; however, it is not 
known whether it is sufficient to drive astrogliosis in the otherwise unperturbed CNS (Okada 
et al., 2006). The ability to induce astrogliosis with LZK overexpression alone in the absence 
of any injury or other insult would provide a new avenue to study the pathophysiological 
roles of astrogliosis in CNS injury and disease (Pekny et al., 2016). Furthermore, LZK 
overexpression in astrocytes led to a widespread upregulation of pSTAT3, again suggesting 
that LZK activates the JAK-STAT pathway in both a cell-autonomous and non-cell-
autonomous manner. Likewise, astrocytic LZK overexpression upregulated the expression of 
SOX9, another molecule that is implicated in astrocyte reactivity (McKillop et al., 2013). 
Future studies are required to dissect the functional interaction between LZK and other 
signaling pathways in regulating astrocytic reactivity. In contrast to the activation of JNK 
(assessed by phospho-JNK [pJNK] levels) by LZK in CNS neurons (Chen et al., 2016), 
pJNK was rarely detected in LZK-overexpressing astrocytes. Instead, robust activation of 
STAT3 and upregulation of SOX9 were observed in astrocytes overexpressing LZK in vivo. 
This suggests cell-type-specific LZK signaling cascades in response to neural injury. Our 
work identifies LZK as a positive regulator of SOX9 and STAT3 pathways in the context of 
astroglial reactivity.
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This work also raised an important question regarding the functional consequences of LZK-
regulated astrogliosis on neural repair, especially considering that the role of reactive 
astrocytes and the glial scar in axonal regeneration has been investigated intensively 
(Anderson et al., 2016; Hara et al., 2017; Silver, 2016). Although LZK-regulated astrogliosis 
appears to promote wound healing, toxicity from systemic LZK overexpression in astrocytes 
has hindered our assessment of the impact on post-injury axon dynamics or behavioral 
recovery, which will likely require a method to locally overexpress LZK in the spinal cord. 
Given their vital roles in a variety of brain regions and the heterogeneity of both healthy and 
reactive astrocytes (Ben Haim and Rowitch, 2017; Khakh and Sofroniew, 2015; Liddelow 
and Barres, 2017), it is conceivable that LZK overexpression elicits a multitude of astroglial 
responses with both beneficial and detrimental consequences. However, LZK overexpression 
in Pv-Cre;LZKOE mice did not lead to animal death or any overt phenotype in Pv-expressing 
neurons, arguing against non-physiological effects of LZK overexpression per se. The 
opposite phenotypes in astrogliosis displayed by mice lacking or overexpressing astrocytic 
LZK further support the role of LZK as a critical regulator of the astroglial response to CNS 
injury.
In our previous work, we identified LZK as a neuron-intrinsic promoter of axon growth and 
regeneration in cultured CNS neurons (Chen et al., 2016). A similar effect of LZK on 
promoting axon growth also has been reported with primary retinal ganglion cells (Welsbie 
et al., 2017). The function of LZK in astrocytes reported here illustrates its role as an injury 
sensor capable of orchestrating a multicellular response to CNS injury. It would be of 
significant interest to explore whether LZK-dependent regulation of astrogliosis can be 
extended to other forms of CNS insult, including diffuse damage, neuroinflammation, and 
neurodegenerative diseases. Along these lines, whole-body inducible deletion of dual 
leucine zipper-bearing linase (DLK, or MAP3K12), a homolog of LZK, was recently 
reported to attenuate astrogliosis in a mouse model of ALS; however, the authors suggested 
that this effect was the result of an indirect effect of neuronal DLK (Le Pichon et al., 2017), 
because the evolutionarily conserved role of DLK in neuronal response to injury is well 
documented (Hammarlund et al., 2009; Miller et al., 2009; Shin et al., 2012; Watkins et al., 
2013; Welsbie et al., 2013; Yan et al., 2009). Regardless, a multicellular role for the same 
signaling molecule in mediating CNS response to insult underscores the importance of 
thoroughly understanding its cell-type-specific functions before effective translational 
strategies can be envisioned. The identification of LZK as a cell-intrinsic signaling molecule 
regulating astroglial reactivity will allow for the testing of important hypotheses regarding 
the complex roles of astrocyte reactivity in CNS injury and disease.
EXPERIMENTAL PROCEDURES
Genetically Modified Mice
All mouse husbandry and experimental procedures were approved by the Institutional 
Animal Care and Use Committee at the University of California San Diego and the 
University of Texas Southwestern Medical Center. Both male and female mice, ages 8–10 
weeks, were used. LZK-targeted mutant mice were generated through the UC San Diego 
Transgenic Mouse and Gene Targeting Core using a mouse embryonic stem cell line 
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obtained from the Knockout Mouse Project (KOMP) Repository as described previously 
(Chen et al., 2016). LZKf/f mice were generated by crossing mice carrying the LZK-targeted 
allele to mice expressing germline flippase (FLP) recombinase (Rodríguez et al., 2000), 
followed by removal of FLP recombinase by breeding to wild-type C57BL/6 mice. LZKf has 
two loxP sites flanking exon 2 where Cre-mediated excision is expected to result in a 
frameshift and thus a null allele. These mice were crossed with the GFAP-CreERT2 line 
(Hirrlinger et al., 2006) to generate GFAP-CreERT2;LZKf/f mice in C57BL/6 background (N 
> 10) for this study. Transgenic LZK conditional overexpressing mice (LZKOE) in FVB 
background were custom made by Applied StemCell. After breeding to C57BL/6 for two 
generations, LZKOE mice were crossed with GFAP-CreERT2 mice (Hirrlinger et al., 2006) 
in C57BL/6 background to generate the GFAP-CreERT2;LZKOE line (see illustration of 
LZKf and LZKOE alleles in Figures 1 and 4 for more details). LZKOE mice were crossed 
with Pv-Cre mice (Hippenmeyer et al., 2005) to generate the Pv-Cre;LZKOE line. Pv-Cre 
knockin allele has the endogenous Pv promoter/enhancer elements directing the expression 
of Cre recombinase, which will allow LZK overexpression in Pv+ cells.
General In Vivo Experimental Design
All of the surgical experiments, tissue processing, data acquisition, and quantification were 
performed by a laboratory member blinded to genotype. For experiments testing the effects 
of astrocyte-specific LZK deletion, 8- to 10-week-old GFAP-CreERT2;LZKf/f mice and their 
LZKf/f littermate controls each were given 75 mg/kg/day tamoxifen by oral gavage for a 
total of 5 gavages (days 1, 2, 3, 4, and 5). For experiments testing the effects of astrocyte-
specific LZK overexpression, 8- to 10-week-old GFAP-CreERT2;LZKOE mice and their 
LZKOE littermate controls each were given 75 mg/kg tamoxifen by oral gavage every other 
day (days 1, 3, and 5), for a total of 3 gavages (the dosage was reduced as compared with 
LZK conditional knockout mice to alleviate animal loss). GFAP-CreERT2;LZKOE mice lose 
weight following tamoxifen-induced LZK overexpression, leading to the death of some 
animals. In all of the mice, 1 week after the last tamoxifen treatment, a surgeon blinded to 
genotype performed spinal cord surgery. Two weeks after surgery, brains and spinal cords 
were collected and subsequently processed for qualitative and quantitative histological 
evaluation. Along the same timeline, uninjured mice were perfused and analyzed 3 weeks 
after the last tamoxifen treatment.
Surgical Procedures
All of the animals underwent general anesthesia by intraperitoneal injection of ketamine and 
xylazine. Using a surgical microscope (Zeiss OPMI 1FC), laminectomy of one vertebra at 
thoracic level T8–T9 was performed. We used a dorsal hemi-crush model as previously 
described by Chen et al., (2017). A pair of no. 5 Dumont forceps (Fine Science Tools) was 
then used to compress the dorsal spinal cord at a depth of 0.7 mm across the entire width of 
the cord for 5 s. This dorsal hemi-crush model allowed for better survival following surgery 
as compared with full spinal cord complete crush and thus was used throughout this study, 
especially given that mice overexpressing astrocyte-specific LZK exhibited reduced survival 
even without injury.
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Statistical Analyses
Unpaired parametric t test or two-way ANOVA followed by post hoc t test using GraphPad 
Prism software calculated the statistical significance in differences between two groups. N 
represents the number of animals per genotype or treatment. For exact values of n, see the 
figure legends and the Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• LZK (MAP3K13) is upregulated in astrocytes after spinal cord injury in adult 
mice
• Astrocytic LZK deletion in adult mice reduces astrogliosis and impairs scar 
formation
• Astrocytic LZK overexpression in adult mice enhances astrogliosis and scar 
formation
• Astrocytic LZK overexpression in uninjured adult CNS induces widespread 
astrogliosis
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Figure 1. Injury-Induced Leucine Zipper-Bearing Kinase Expression in Astrocytes and 
Conditional Gene Deletion
(A) Representative images of endogenous LZK and glial fibrillary astrocyte protein (GFAP) 
immunostaining in the spinal cords of uninjured or injured wild-type (WT) mice (14 days 
after spinal cord injury [SCI]), taken 0.5–1 mm from the injury site on horizontal sections.
(B) Diagram of the LZK conditional knockout allele (LZKf). Cre-mediated excision of exon 
2 would result in a frameshift and thus a null allele. Black arrows mark the positions of PCR 
primers for genotyping.
(C) Genomic PCR genotyping of WT, LZKf/f, and GFAP-CreERT2;LZKf/f mice.
(D) Immunostaining of endogenous LZK and GFAP in the spinal cords of tamoxifen-
pretreated LZKf/f control and GFAP-CreERT2;LZKf/f mice 14 days after spinal cord injury 
(SCI), with images taken 0.5–1 mm from the injury site. Dotted lines demarcate white (W) 
matter and gray (G) matter.
Scale bars represent 100 μm. See also Figure S1.
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Figure 2. LZK Deletion in Adult Astrocytes Impaired Astrogliosis 14 Days after Spinal Cord 
Injury
(A) Representative images of GFAP and DAPI nuclear staining centered at the spinal cord 
injury site from tamoxifen-pretreated LZKf/f control and GFAP-CreERT2;LZKf/f mice. Note 
that the GFAP− lesion core is enveloped by GFAP+ astrocytes and their processes. Areas 
within the white boxes are shown in high magnification (rightmost panels) to illustrate 
astrocytic processes parallel (arrows) to the lesion border in control mice but perpendicular 
(arrowheads) in astrocytic LZK knockout mice. Figures are composites of smaller 
microscopy images. Scale bar represents 200 μm (low magnification) and 100 μm (high 
magnification).
(B) Quantification of lesion size in LZKf/f control versus GFAP-CreERT2;LZKf/f mice. n = 8 
mice per genotype, *p < 0.05 by unpaired parametric t test.
(C) GFAP immunofluorescence intensity in the injured spinal cords of LZKf/f control versus 
GFAP-CreERT2;LZKf/f mice in 9 zones (each the width of the spinal cord and length of 250 
μm). Zone 1 starts at the lesion border, followed by the other zones placed sequentially away 
from the injury site and immediately adjacent to one another, as adapted from Wanner et al., 
(2013). n = 8 mice per genotype, *p < 0.05 by two-way ANOVA followed by post hoc 
multiple t test between groups for each zone.
Error bar represents SEM.
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Figure 3. LZK Deletion in Adult Astrocytes Reduced Astrogliosis in the Injured Spinal Cord as 
Assessed by Vimentin Expression and Astrocyte Proliferation
(A) Representative images of vimentin and DAPI staining at the spinal cord injury site of 
tamoxifen-treated LZKf/f control and GFAP-CreERT2;LZKf/f mice 14 days post-injury (dpi). 
Astrocytes strongly expressing vimentin enclose the lesion core. Areas within white boxes 
are shown in high magnification (rightmost panels) to illustrate astrocytic processes parallel 
(arrows) and perpendicular (arrowheads) to the lesion border in control mice and mice 
lacking astrocytic LZK, respectively. Figures are composites of smaller microscopy images.
(B) Representative images of DAPI, SOX9, and Ki67 co-immunofluorescence staining 
within 250 μm of the spinal cord injury site of tamoxifen-treated LZKf/f control and GFAP-
CreERT2;LZKf/f mice at 7 dpi.
(C) Quantification of vimentin immunofluorescence intensity at and within 250 μm of the 
lesion border in control versus astrocytic LZK knockout mice 14 dpi. n = 4 per genotype, *p 
< 0.05 by two-tailed unpaired parametric t test.
(D) Quantification of the numbers of proliferating astrocytes by Ki67+SOX9+ co-labeling 
within 250 μm of spinal cord injury site in control versus astrocytic LZK knockout mice 7 
dpi. n = 3 per genotype, *p < 0.05 by two-tailed unpaired parametric t test.
Scale bars, 200 μm (A, low magnification), 100 μm (A, high magnification, rightmost 
panels), and 50 μm (B). See also Figure S2.
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Figure 4. LZK Overexpression in Adult Astrocytes Enhanced Astrogliosis and Reduced Lesion 
Size 14 dpi
(A) Diagram of the LZK conditional overexpression transgene (LZKOE). LZKOE has two 
loxP sites flanking a STOP cassette upstream of an LZK-T2A-tdTomato (tdT) fusion gene. 
Cre-mediated excision of STOP would activate LZK-T2A-tdT, leading to overexpression of 
LZK and the associated fluorescent reporter tdT. Black arrows mark the positions of PCR 
primers for genotyping.
(B) Genomic PCR genotyping of WT, LZKOE, and GFAP-CreERT2;LZKOE mice.
(C) Representative images taken from perilesional area (0.5–1 mm from the injury site), 
showing that tdT activation was associated with LZK overexpression, GFAP upregulation, 
and astrocyte hypertrophy in tamoxifen-pretreated GFAP-CreERT2;LZKOE mice as 
compared with LZKOE control mice. Note LZK and GFAP co-localization in the merged 
panels.
(D) Representative images of GFAP immunostaining, tdT direct fluorescence, and DAPI 
nuclear staining centered at the injury site in the spinal cords of tamoxifen-pretreated 
LZKOE control mice and GFAP-CreERT2;LZKOE mice. Areas within the white boxes are 
shown in high magnification (rightmost panels) to illustrate the lesion borders lined by 
GFAP+ astrocytes. Note the presence of tdT+ astrocytes and the more compact lesion in the 
GFAP-CreERT2;LZKOE mouse. Figures are composites of smaller microscopy images. 
Scale bar represents 250 μm (low magnification), 100 μm (high magnification).
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(E) Quantification of lesion size in LZKOE control versus GFAP-CreERT2;LZKOE mice. n = 
5 for LZKOE mice; n = 3 for GFAP-CreERT2;LZKOE mice; p = 0.08 by unpaired parametric 
t test. See Figure S3 for an independent replicate experiment by a second surgeon.
(F) GFAP immunofluorescence intensity in the injured spinal cords of LZKf/f control versus 
GFAP-CreERT2;LZKf/f mice in 9 zones defined similarly in Figure 2C. Same numbers of 
mice as in (E); *p < 0.05 by two-way ANOVA followed by post hoc multiple t test between 
groups for each zone. Error bar represents SEM.
See also Figure S3.
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Figure 5. LZK Overexpression in Adult Astrocytes Induced Widespread Astrogliosis in the 
Absense of Injury as Assessed by GFAP Immunoreactivity
(A and B) Representative images of GFAP immunostaining and tdT direct fluorescence on 
horizontal (A) and transverse (B) spinal cord sections from tamoxifen-treated, uninjured 
LZKOE control and GFAP-CreERT2;LZKOE mice.
(C) Quantification of GFAP immunofluorescence intensity on horizontal spinal cord sections 
from LZKOE control versus GFAP-CreERT2;LZKOE mice after tamoxifen treatment. n = 3 
mice per genotype, *p < 0.05 by unpaired parametric t test.
(D) Higher magnification images of LZK, tdT, and GFAP signals on horizontal spinal cord 
sections from tamoxifen-treated, uninjured mice, showing co-localization of LZK/GFAP and 
noting similar patterns of LZK with tdT direct fluorescence. Dotted lines demarcate white 
(W) matter and gray (G) matter.
(E) LZK, GFAP immunostaining, and tdT direct fluorescence in the brains of tamoxifen-
treated LZKOE control and GFAP-CreERT2;LZKOE mice.
(F) Quantification of GFAP immunofluorescence intensity in the cerebral cortices of 
tamoxifen-treated LZKOE versus GFAP-CreERT2;LZKOE mice. n = 3 mice per genotype, *p 
< 0.05 by unpaired parametric t test. Error bar represents SEM.
Scale bars, 250 μm (A and B), 100 μm (D), and 1 mm (E). See also Figures S4 and S5.
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Figure 6. LZK Overexpression in Adult Astrocytes Induced Widespread Astrogliosis in the 
Absence of Injury as Assessed by Vimentin Immunoreactivity and Astrocyte Proliferation
(A and B) Vimentin, GFAP immunostaining, and tdT direct fluorescence on coronal sections 
from the hippocampal region of the brains (A) and horizontal spinal cord sections (B) of 
LZKOE control and GFAP-CreERT2;LZKOE mice after tamoxifen treatment. Note the 
similarly upregulated vimentin and GFAP immunoreactivity in GFAP-CreERT2;LZKOE 
mice.
(C) Ki67, GFAP immunostaining, and tdT direct fluorescence in the cerebral cortices (brain) 
and spinal cord gray matter from LZKOE control and GFAP-CreERT2;LZKOE mice.
(D) Quantification of Ki67+GFAP+ cell numbers in the cerebral cortices (brain) and spinal 
cord gray matter of LZKOE control and GFAP-CreERT2;LZKOE mice. n = 3 per group, p 
value determined by unpaired parametric t test. Error bar represents SEM.
Scale bars 250 μm (A and B) and 50 μm (C). (A) and (B) are composites of smaller 
microscopy images.
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Figure 7. LZK Positively Regulates SOX9 and pSTAT3 in Adult Astrocytes In Vivo
(A) Immunofluorescence staining of SOX9 on coronal brain sections from LZKOE control 
and GFAP-CreERT2;LZKOE mice. Lower-magnification images are shown in the left panels, 
with cerebral cortical areas within the white boxes shown in high magnification in the right 
panels. Note the higher levels of SOX9 immunoreactivity in GFAP-CreERT2;LZKOE mice.
(B) Quantification of SOX9+ cell number and SOX9 immunofluorescence intensity in the 
cerebral cortices of LZKOE control and GFAP-CreERT2;LZKOE mice. n = 3 per group, p 
value determined by unpaired parametric t test.
(C) Immunofluorescence staining of SOX9 on transverse spinal cord sections. Note the 
higher levels of SOX9 immunoreactivity in GFAP-CreERT2;LZKOE mice.
(D) Quantification of SOX9+ cell number and SOX9 immunofluorescence intensity in the 
spinal cord gray matter of LZKOE control and GFAP-CreERT2;LZKOE mice. n = 3 per 
group, p value determined by unpaired parametric t test.
(E) Immunofluorescence detection of GFAP, pSTAT3, and tdT on horizontal spinal cord 
sections of LZKOE control (left panels) and GFAP-CreERT2;LZKOE mice (right panels). 
Arrows represent tdT/pSTAT3 co-labeled cells; arrowheads represent GFAP/pSTAT3 co-
labeled cells but without tdT co-labeling. Quantification of these data (shown in Figures 
S3D and S3E) indicates that LZK overexpression in adult astrocytes increased pSTAT3+ 
cells/astrocytes in the uninjured spinal cord.
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Scale bars, 500 μm (A, low magnification), 100 μm (A, high magnification), 250 μm (C), 
200 μm (E, low magnification), 50 μm (E, high magnification). (A), (C), and (E) are 
composites of smaller microscopy images.
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